secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2022-11-02T23:59:59+00:00
Accession:  0001193125-22-275466
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

David P. Ryan appointed to board; Ansbert Gadicke resigns as director at Cullinan Oncology
--------------------------------------------------------------------------------

- David P. Ryan, M.D. appointed as Class II director effective Nov 1, 2022.
- Dr. Ryan brings over 20 years of oncology experience; Clinical Director at MGH Cancer Center since 2012.
- Received option grant with $250,000 fair value, vesting one-third annually over three years.
- Ansbert Gadicke, M.D. resigned as director effective Nov 1, 2022; no disagreement with Company.
- Dr. Ryan appointed to Compensation Committee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000119312522275466/0001193125-22-275466-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000119312522275466/d332832d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-275466

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer